Notice of Selection of the Most Advantageous Offer Request for proposal RFP – 027286 – VALUATION OF COMBINATION THERAPY INVOLVING A TEST COMPOUND AND A SELECTED STANDARD-OF-CARE AGENT IN THREE-DIMENSIONAL CANCER MODELS WITH CONSIDERATION OF THE IMMUNE MICROENVIRONMENT 

In connection with the implementation of the project: 

• „Clinical trial of the first phase (Ia/Ib) of a fusion protein with a dual anticancer mechanism”, financed from the state budget by the Medical Research Agency (project no. 2022/ABM/05/000006-00) under the Call for the Development of Targeted or Personalized Medicine Based on Cell Therapies or Protein Products, 

Adamed Pharma S.A. hereby informs that the contract will be awarded to the Contractor whose offer met all participation requirements and was the most advantageous for the respective items. 

Accordingly, the contract will be awarded to: Real Research S.A.